Literature DB >> 8032658

Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle.

G S Baxter1, O E Murphy, T P Blackburn.   

Abstract

1. The present study was undertaken to isolate and characterize pharmacologically homogeneous populations of 5-hydroxytryptamine (5-HT) receptors from a possible mixed receptor population mediating concentration of the longitudinal muscle of rat stomach fundus. Our aim was to extend the pharmacological characterization of the 5-HT2B receptor which is reported to be expressed in this preparation. 2. To minimize spontaneous activity and any influence of circular muscle on the contractile response, narrow (1-1.5 x 20 mm) segments of mucosa-denuded longitudinal muscle were used. Under these conditions, blockade of monoamine oxidase with pargyline (100 microM for 15 min) caused a leftward displacement of concentration-effect curves for both 5-methoxytryptamine (5-MeO-T) and tryptamine. Neither pargyline nor a number of uptake inhibitors affected responses to 5-HT. 3. In pargyline pretreated preparations, the order of potency of a number of tryptamine analogues was as follows: 5-MeO-T > or = alpha-Me-5-HT > or = 5-HT > 5-carboxamidotryptamine (5-CT) > tryptamine > 2-Me-5-HT. In addition several ligands known to act as agonists at either 5-HT2A or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive. With the exception of 2-Me-5-HT and m-CPP, most agonists produced monophasic concentration-effect curves consistent with an interaction at a single site. High concentrations of 2-Me-5-HT evoked relaxations which were blocked by phentolamine (1 MicroM) suggesting an interaction with alpha-adrenoceptors. m-CPP often evoked biphasic concentration-effect curves with a second contractile phase which was insensitive to yohimbine at concentrations higher than required for antagonism of responses to 5-HT.4. LY 53857, methiothepin, methysergide, ritanserin and ICI 170809 were potent but non-surmountable antagonists of 5-HT in rat fundus. In contrast, several ligands behaved as surmountable antagonists with the following order of potency: rauwolscine >yohimbine = mesulergine > mianserin = SB 204070 >WY 26703 > SB 200646> pirenpirone> renzapride. DAU 6285, granisetron, spiperone, ketanserin,phentolamine and GR 127935 did not affect responses to 5-HT at concentrations up to 1 pM. The agonist and concentration independent profile of antagonism supported a single site interaction for both agonists and antagonists.5. We conclude that despite small differences concerning the enantiomeric selectivity and affinity of rauwolscine and yohimbine, the close pharmacological identity of 5-HT receptors in rat stomach fundus and the recently cloned 5-HT2B receptor is maintained. SB 200646, which demonstrates some selectivity for 5-HT receptors in rat stomach fundus, should provide a useful ligand for confirmation of this view and allow discrimination of 5-HT2B function both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8032658      PMCID: PMC1910288          DOI: 10.1111/j.1476-5381.1994.tb13072.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

1.  Phenoxybenzamine antagonism of tryptamines, their indene isosteres and 5-hydroxytryptamine in the rat stomach fundus preparation.

Authors:  J C Winter; P K Gessner
Journal:  J Pharmacol Exp Ther       Date:  1968-08       Impact factor: 4.030

2.  Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor.

Authors:  D B Wainscott; M L Cohen; K W Schenck; J E Audia; J S Nissen; M Baez; J D Kursar; V L Lucaites; D L Nelson
Journal:  Mol Pharmacol       Date:  1993-03       Impact factor: 4.436

Review 3.  A proposed new nomenclature for 5-HT receptors.

Authors:  P P Humphrey; P Hartig; D Hoyer
Journal:  Trends Pharmacol Sci       Date:  1993-06       Impact factor: 14.819

4.  Serotonin. I. receptors involved in its action.

Authors:  J Offermeier; E J Ariëns
Journal:  Arch Int Pharmacodyn Ther       Date:  1966-11

5.  The relative activities of some tryptamine analogues on the isolated rat stomach strip preparation.

Authors:  J R VANE
Journal:  Br J Pharmacol Chemother       Date:  1959-03

6.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

7.  Endothelial relaxing 5-hydroxytryptamine receptors in the rat jugular vein: similarity with the 5-hydroxytryptamine1C receptor.

Authors:  M Bodelsson; K Törnebrandt; B Arneklo-Nobin
Journal:  J Pharmacol Exp Ther       Date:  1993-02       Impact factor: 4.030

8.  Actions of some analogues of 5-hydroxytryptamine on the isolated rat uterus and the rat fundus strip preparations.

Authors:  R B BARLOW; I KHAN
Journal:  Br J Pharmacol Chemother       Date:  1959-06

9.  Alpha 2-adrenoceptor antagonism and other pharmacological antagonist properties of some substituted benzoquinolizines and yohimbine in vitro.

Authors:  N Lattimer; R P McAdams; K F Rhodes; S Sharma; S J Turner; J F Waterfall
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-10       Impact factor: 3.000

10.  Relationship between serotonin and tryptamine receptors in the rat stomach fundus.

Authors:  M L Cohen; L A Wittenauer
Journal:  J Pharmacol Exp Ther       Date:  1985-04       Impact factor: 4.030

View more
  21 in total

1.  Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT(2B) receptors.

Authors:  E Glusa; H H Pertz
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

2.  Smooth muscle 5-HT2A receptors mediating contraction of porcine isolated proximal stomach strips.

Authors:  P Janssen; N H Prins; A L Meulemans; R A Lefebvre
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

3.  Inhibition of colonic motility and defecation by RS-127445 suggests an involvement of the 5-HT2B receptor in rodent large bowel physiology.

Authors:  A K Bassil; C M Taylor; V J N Bolton; K M Gray; J D Brown; L Cutler; S G Summerfield; G Bruton; W J Winchester; K Lee; G J Sanger
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

4.  RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist.

Authors:  D W Bonhaus; L A Flippin; R J Greenhouse; S Jaime; C Rocha; M Dawson; K Van Natta; L K Chang; T Pulido-Rios; A Webber; E Leung; R M Eglen; G R Martin
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

5.  Selective inhibitory effects of niflumic acid on 5-HT-induced contraction of the rat isolated stomach fundus.

Authors:  H C Scarparo; G C Santos; J H Leal-Cardoso; D N Criddle
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

6.  Functional evidence for a 5-HT2B receptor mediating contraction of longitudinal muscle in human small intestine.

Authors:  R A Borman; D E Burleigh
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

7.  In vivo characterization of 5-HT1A receptor-mediated gastric relaxation in conscious dogs.

Authors:  P Janssen; N H Prins; B Moreaux; A L Meulemans; R A Lefebvre
Journal:  Br J Pharmacol       Date:  2003-09-29       Impact factor: 8.739

8.  Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.

Authors:  Antony R Knight; Anil Misra; Kathleen Quirk; Karen Benwell; Dean Revell; Guy Kennett; Mike Bickerdike
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-30       Impact factor: 3.000

9.  Differential regulation of rat peripheral 5-HT(2A) and 5-HT(2B) receptor systems: influence of drug treatment.

Authors:  M J Enguix; L Sánchez; M Villazón; J Brea; H Tristán; H J Caruncho; M I Cadavid; M I Loza
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-07-12       Impact factor: 3.000

10.  In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties.

Authors:  G A Kennett; M D Wood; F Bright; J Cilia; D C Piper; T Gager; D Thomas; G S Baxter; I T Forbes; P Ham; T P Blackburn
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.